SOX2 Is a Univocal Marker for Human Oral Mucosa Epithelium Useful in Post-COMET Patient Characterization

Int J Mol Sci. 2022 May 21;23(10):5785. doi: 10.3390/ijms23105785.

Abstract

Total bilateral Limbal Stem Cells Deficiency is a pathologic condition of the ocular surface due to loss or impairment of corneal stem cell function, altering homeostasis of the corneal epithelium. Cultivated Oral Mucosa Epithelial Transplantation (COMET) is the only autologous treatment for this pathology. During the follow-up, a proper characterization of the transplanted oral mucosa on the ocular surface supports understanding the regenerative process. The previously proposed markers for oral mucosa identification (e.g., keratins 3 and 13) are co-expressed by corneal and conjunctival epithelia. Here, we propose a new specific marker to distinguish human oral mucosa from the epithelia of the ocular surface. We compared the transcriptome of holoclones (stem cells) from the human oral mucosa, limbal and conjunctival cultures by microarray assay. High expression of SOX2 identified the oral mucosa vs. cornea and conjunctiva, while PAX6 was highly expressed in corneal and conjunctival epithelia. The transcripts were validated by qPCR, and immunological methods identified the related proteins. Finally, the proposed markers were used to analyze a 10-year follow-up aniridic patient treated by COMET. These findings will support the follow-up analysis of COMET treated patients and help to shed light on the mechanism of corneal repair and regeneration.

Keywords: COMET; LSCD; PAX6; SOX2; aniridia; biomarker; cornea; homeostasis; ocular surface; oral mucosa.

MeSH terms

  • Biomarkers
  • Cornea / pathology
  • Corneal Diseases* / genetics
  • Corneal Diseases* / metabolism
  • Corneal Diseases* / pathology
  • Epithelium, Corneal*
  • Humans
  • Mouth Mucosa / pathology
  • SOXB1 Transcription Factors / genetics
  • SOXB1 Transcription Factors / metabolism
  • Stem Cells / metabolism

Substances

  • Biomarkers
  • SOX2 protein, human
  • SOXB1 Transcription Factors

Grants and funding

This study was funded by the Awards “Lombardia è Ricerca 2018” and “Louis Jeantet Award 2020” and by Holostem Terapie Avanzate s.r.l. and by Regione Emilia-Romagna (area 1b, medicina rigenerativa) and POR-FESR 2007-13-Tecnopolo.